Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations-Reference-Cited by-同舟云学术

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Published:2018-12 Issue:12 Volume:13 Page:1884-1896
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Toki Maria I.,Mani Nikita,Smithy James W.,Liu Yuting,Altan Mehmet,Wasserman Brad,Tuktamyshov Rasikh,Schalper Kurt,Syrigos Konstantinos N.,Rimm David L.

Funder

NIH

Yale SPORE in Lung Cancer

Stand Up to Cancer

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference57 articles.

1. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer;Borghaei;N Engl J Med,2015

2. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer;Brahmer;N Engl J Med,2015

3. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial;Herbst;Lancet,2016

4. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer;Reck;N Engl J Med,2016

5. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC;Exploration of Targeted Anti-tumor Therapy;2024-07-19

2. A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non‐small cell lung cancer;Cancer Science;2024-06-18

3. Prognostic Value of KRAS Mutations in Relation to PDL1 Expression and Immunotherapy Treatment in Adenocarcinoma and Squamous Cell Carcinoma Patients: A Greek Cohort Study;Journal of Personalized Medicine;2024-04-25

4. Prognostic value of predominant subtype in pathological stage II–III lung adenocarcinoma with epidermal growth factor receptor mutation;Lung Cancer;2024-02

5. Leveraging an immune cell signature to improve the survival and immunotherapy response of lung adenocarcinoma;Journal of Cancer;2024